News und Analysen
QIAGEN und DiaSorin erweitern Zugang zu Tests auf latente TB in den USA mit FDA-Zulassung des QuantiFERON®-TB Gold Plus Tests für LIAISON®-XS-Plattformen
QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) und DiaSorin (FTSE MIB: DIA) gaben heute bekannt, dass die US-amerikanische Food and Drug Administration (FDA) den LIAISON® QuantiFERON®-TB Gold
QIAGEN bestätigt Wirksamkeit seiner PCR-Tests auf SARS-CoV-2 angesichts der neuen Coronavirus-Variante B.1.1.529
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) gab heute bekannt, dass die auf Polymerase-Kettenreaktionen (Polymerase Chain Reaction, PCR) basierenden Tests des Unternehmens auch
QIAGEN reaffirms effectiveness of its SARS-CoV-2 PCR tests in light of the new coronavirus variant B.1.1.529
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced its polymerase chain reaction (PCR) tests remain accurate and effective in detecting SARS-CoV-2 infections in light of the
Lysogene Secures a €4.3 Million Non-dilutive Financing From Bpifrance to Support Its Development
Regulatory News:
Lysogene (FR0013233475 – LYS) (Paris:LYS), a phase 3 gene therapy platform Company targeting central nervous system (CNS) diseases, announced today that it has secured a €4.3
Vifor Pharma supports Iron Deficiency Day 2021: Call to action for early iron deficiency diagnosis
Already for the seventh consecutive year of Iron Deficiency Day, Vifor Pharma is supporting a growing international alliance including the Heart Failure Policy Network, European Kidney Health
Quantum Genomics signs an exclusive license agreement with Teva Israel Ltd.
Press release
Paris, November 25, 2021
Quantum Genomics signs an exclusive license agreement with Teva Israel Ltd.
- Quantum Genomics will receive up to $11 M in payments and 25% minimum up to 30%
Bedarf an Strom und erneuerbaren Energien wächst
Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference
Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a discussion with Bob Smith, Vice President, Pfizer Rare Disease, at the 4th Annual Evercore ISI
Puma Biotechnology Announces U.S Patent Term Extension for NERLYNX® (neratinib)
Puma Biotechnology, Inc. (Nasdaq: PBYI), a biopharmaceutical company, announced that the United States Patent and Trademark Office (USPTO) issued a Patent Term Extension Certificate for U.S. Patent
Agilent to Present at Evercore ISI Virtual Healthcare Conference
Agilent Technologies Inc. (NYSE: A) today announced the company’s presentation at the Evercore ISI Virtual Healthcare Conference will be made available by webcast. The details:
Evercore ISI
QUANTUM GENOMICS : Dr. Catherine Llorens-Cortes receives the 2021 Emilia Valori Prize from the French Academy of Sciences
Press release
Paris, November 23, 2021
Dr. Catherine Llorens-Cortes receives the 2021 Emilia Valori Prize from the French Academy of Sciences
Quantum Genomics (Euronext Growth : ALQGC, OTCQX
LivaNova to Present at the Piper Sandler 33rd Annual Virtual Healthcare Conference
LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, today announced that Damien McDonald, Chief Executive Officer, will participate in discussions at the Piper
IMV Inc. to Present at the Piper Sandler Virtual Healthcare Conference
IMV Inc. (Nasdaq: IMV; TSX: IMV) (“IMV” or “the Company”), a clinical-stage company developing a portfolio of immune-educating cancer therapies based on its novel DPX platform, today announced that
Novocure to Participate in Two Upcoming Investor Conferences
Novocure (NASDAQ: NVCR) announced today it will participate in two upcoming investor conferences.
William Doyle, Novocure’s Executive Chairman, and Ashley Cordova, Novocure’s Chief Financial
Agilent Reports Fourth-Quarter and Fiscal Year 2021 Financial Results
Agilent Technologies Inc. (NYSE: A) today reported revenue of $1.66 billion for the fourth quarter ended Oct. 31, 2021, up 12% year over year (core(1) growth of 11%). Revenue for the full year was
Humana Expands Value-Based Agreement with Hutchinson Clinic to Increase Medicare Advantage Access in Central Kansas
Humana Inc. (NYSE: HUM), a leading health and wellness company, has expanded its value-based care agreement with Hutchinson Clinic, a physician specialty group with a 60-year legacy of focusing on
Transgene and NEC Announce Positive Preliminary Data From Phase I Studies of TG4050, a Novel Individualized Neoantigen Cancer Vaccine
Regulatory News:
Transgene (Euronext Paris: TNG) (Paris:TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, and NEC Corporation (NEC; TSE:
Humana Announces Value-Based Agreement with Allina Health in Minnesota
Humana Inc. (NYSE: HUM), a leading health and well-being company, and Allina Health are expanding their existing agreement to focus on value-based care for Humana’s Medicare Advantage members in
IMV Inc. Announces Chief Financial Officer to Retire
IMV Inc. (NASDAQ: IMV; TSX: IMV) (“IMV” or “the Company”), a clinical-stage company developing a portfolio of immune-educating cancer therapies based on its novel DPX platform, today announced that
ICON Releases Environmental, Social and Governance Report
ICON plc (NASDAQ:ICLR) announced today the release of its 2020 Environmental, Social and Governance (ESG) Report. With the completion of ICON’s acquisition of PRA Health Sciences, the report
Novocure Announces Last Patient Enrolled in Phase 3 Pivotal LUNAR Trial of Tumor Treating Fields in Non-small Cell Lung Cancer
Novocure (NASDAQ: NVCR) today announced that the final patient has been enrolled in the phase 3 pivotal LUNAR trial evaluating the efficacy of Tumor Treating Fields (TTFields) together with immune
Deciphera Receives European Commission Approval of QINLOCK® for the Treatment of Fourth-Line Gastrointestinal Stromal Tumor
Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a commercial-stage biopharmaceutical company developing innovative medicines to improve the lives of people with cancer, today announced that the
Follow-Up Data From Phase 3 Trial of Pfizer-BioNTech COVID-19 Vaccine Support Safety and High Efficacy in Adolescents 12 Through 15 Years of Age
Pfizer Inc. (NYSE:PFE) and BioNTech SE (Nasdaq:BNTX) today announced topline results from a longer-term analysis of the safety and efficacy of their COVID-19 vaccine in individuals 12 through 15
GenSight Biologics to Host Key Opinion Leader Webcast on Outcomes Among Compassionate Use Patients Treated Bilaterally with LUMEVOQ® in the US
Regulatory News:
GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal
Vifor Pharma to spearhead development of vascular calcification field, through acquisition of Sanifit Therapeutics and Inositec AG
Regulatory News:
AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR
Vifor Pharma has announced the acquisition of Sanifit Therapeutics, a Spanish clinical-stage cardio-renal biopharmaceutical company